Growth Hormone in the Treatment of HIV-Associated Wasting
|ClinicalTrials.gov Identifier: NCT00489528|
Recruitment Status : Completed
First Posted : June 21, 2007
Last Update Posted : October 22, 2013
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections HIV Wasting Syndrome||Drug: Somatropin; Recombinant human growth hormone (r hGH)||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of Recombinant Human Growth Hormone (Serostim) in the Treatment of HIV-Associated Catabolism/Wasting|
|Study Start Date :||July 1997|
|Study Completion Date :||March 2002|
- To confirm the clinical efficacy of Serostim compared with placebo, based on an endpoint of exercise function change.
- To establish an optimal dose of Serostim, based on the endpoint of lean body mass (LBM) change.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00489528
|Study Director:||Elizabeth Svanbert, MD, PhD|